Anew Medical (WENA) said Tuesday it plans to advance its patented Klotho gene therapy program for neurodegenerative disorders.
Anew said it has "compelling initial data" suggesting that elevated levels of Klotho contributes to longer, healthier lifespans, while people with depleted levels of the gene "are more susceptible to neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's Disease."
The company said it plans to advance its program in clinical trials, in the commercialization of a diagnostic that will enable doctors to quantify levels of Klotho gene and protein isoforms in blood samples, and in age-related disorders such as memory loss, osteoporosis, and sarcopenia.
Anew Medical rose 48% to $2.14 in premarket trading.
Price: 2.3800, Change: +0.93, Percent Change: +64.14
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.